Innate Pharma (IPHA)
(Delayed Data from NSDQ)
$2.15 USD
+0.01 (0.23%)
Updated Aug 6, 2025 01:49 PM ET
After-Market: $2.20 +0.06 (2.56%) 4:40 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IPHA 2.15 +0.01(0.23%)
Will IPHA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IPHA based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for IPHA
Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025 | IPHA Stock News
Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference | IPHA ...
12 Health Care Stocks Moving In Monday's Pre-Market Session
Innate Pharma (IPHA) Receives Buy Rating with Encouraging Outlook
Innate Pharma initiated with bullish view at BTIG, here's why